TABLE 2.

Tolerability profiles: local and systemic reactions according to vaccine group

ReactionNo. (%) of HIV-1-seronegative subjectsPa (A vs B)No. (%) of HIV-1-seropositive subjectsP (C vs D)
Group A (Fluad) (n = 81)Group B (Agrippal) (n = 80)Group C (Fluad) (n = 46)Group D (Agrippal) (n = 49)
Local
    Redness6 (7.4)2 (2.5)NS3 (6.5)3 (6.1)NS
    Pain44 (54.3)19 (23.7)<0.0116 (34.8)9 (18.4)NS
    Induration18 (22)5 (6.2)<0.018 (17.4)5 (10.2)NS
    Ecchymosis2 (2.5)0 (0)NS1 (2.1)1 (2)NS
Systemic
    Shivering16 (19.7)7 (8.7)<0.0513 (28.3)5 (10.2)<0.05
    General malaise27 (33.3)13 (16.2)<0.0514 (30.4)9 (18.4)NS
    Headache21 (25.9)8 (10)<0.0114 (30.4)11 (22.4)NS
    Sweating9 (11.1)4 (5)NS6 (13)4 (8.1)NS
    Myalgia12 (14.8)5 (6.2)NS6 (13)2 (4.1)NS
    Asthenia14 (17.3)5 (6.2)<0.055 (10.9)3 (6.1)NS
    Arthralgia10 (12.3)6 (7.5)NS6 (13)3 (6.1)NS
    Fever23 (28.4)4 (5)<0.0111 (23.9)2 (4.1)<0.01
  • a NS, not significant.